SLC5A2 and type 2 diabetes mellitus: Similarly, with SGLT-2 inhibitors, large trials designed to demonstrate their cardiovascular safety showed that four of the FDA-approved GLP-1 receptor agonists were superior to placebo in lowering the risk for major adverse cardiovascular events in high-risk patients with T2DM: liraglutide, albiglutide, semaglutide, and dulaglutide (Table 2) [32,33,34,35,36,37,38,39,40,41].